The evolving treatment of anal cancer: How are we doing?

M. H. Whiteford, Kenneth Stevens, S. Oh, Karen Deveney, R. Billingham, T. X. O'Connell, W. P. Schecter, S. M. Wren, T. R. Schrock, C. De Virgilio, T. R. Russell, Deveney

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Hypothesis: The adaptation of new techniques in treatment of epidermoid carcinoma of the anal canal during the past 3 decades has improved clinical outcomes. Design: Retrospective consecutive case review. Setting: A university hospital and Veterans Affairs medical center. Patients: Medical records of 76 consecutive patients treated for invasive epidermoid cancer of the anal canal between 1970 and 1999 were reviewed. Twenty-one patients were excluded because of inadequate staging information and/or follow-up of less than 12 months. Main Outcome Measures: Locoregional recurrence, survival, colostomy-free survival, and morbidity. Results: Fifty-five patients composed the study population. Ten were treated during decade 1 (1970-1979), 16 in decade 2 (1980-1989), and 29 in decade 3 (1990-1999). Mean age and sex distributions were similar. The prevailing primary treatment modality changed during the course of the study from sequential treatment (chemotherapy then radiation therapy then radical surgery) to concurrent chemoradiation (70% and 0% of cases, respectively, in decade 1 to 7% and 76% of cases, respectively, in decade 3). Locoregional control (50%, 81%, and 93%; P=.01), crude survival (median, 28, 30, and 76 months), and colostomy-free survival (mean, 13, 90, and 80 months) improved during the 3 decades. There were no differences in major complications during the 3 decades (40%, 56%, and 41%). Conclusion: Primary treatment with concurrent chemoradiation has improved the local recurrence, survival, and colostomy-free survival rates in patients with invasive epidermoid carcinoma of the anal canal without increasing major morbidity.

Original languageEnglish (US)
Pages (from-to)886-891
Number of pages6
JournalArchives of Surgery
Volume136
Issue number8
StatePublished - 2001

Fingerprint

Anus Neoplasms
Colostomy
Anal Canal
Survival
Squamous Cell Carcinoma
Morbidity
Therapeutics
Recurrence
Sex Distribution
Age Distribution
Veterans
Medical Records
Radiotherapy
Survival Rate
Outcome Assessment (Health Care)
Drug Therapy
Population
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Whiteford, M. H., Stevens, K., Oh, S., Deveney, K., Billingham, R., O'Connell, T. X., ... Deveney (2001). The evolving treatment of anal cancer: How are we doing? Archives of Surgery, 136(8), 886-891.

The evolving treatment of anal cancer : How are we doing? / Whiteford, M. H.; Stevens, Kenneth; Oh, S.; Deveney, Karen; Billingham, R.; O'Connell, T. X.; Schecter, W. P.; Wren, S. M.; Schrock, T. R.; De Virgilio, C.; Russell, T. R.; Deveney.

In: Archives of Surgery, Vol. 136, No. 8, 2001, p. 886-891.

Research output: Contribution to journalArticle

Whiteford, MH, Stevens, K, Oh, S, Deveney, K, Billingham, R, O'Connell, TX, Schecter, WP, Wren, SM, Schrock, TR, De Virgilio, C, Russell, TR & Deveney 2001, 'The evolving treatment of anal cancer: How are we doing?', Archives of Surgery, vol. 136, no. 8, pp. 886-891.
Whiteford MH, Stevens K, Oh S, Deveney K, Billingham R, O'Connell TX et al. The evolving treatment of anal cancer: How are we doing? Archives of Surgery. 2001;136(8):886-891.
Whiteford, M. H. ; Stevens, Kenneth ; Oh, S. ; Deveney, Karen ; Billingham, R. ; O'Connell, T. X. ; Schecter, W. P. ; Wren, S. M. ; Schrock, T. R. ; De Virgilio, C. ; Russell, T. R. ; Deveney. / The evolving treatment of anal cancer : How are we doing?. In: Archives of Surgery. 2001 ; Vol. 136, No. 8. pp. 886-891.
@article{b33980aee59b41c18175f0ee739ca7a2,
title = "The evolving treatment of anal cancer: How are we doing?",
abstract = "Hypothesis: The adaptation of new techniques in treatment of epidermoid carcinoma of the anal canal during the past 3 decades has improved clinical outcomes. Design: Retrospective consecutive case review. Setting: A university hospital and Veterans Affairs medical center. Patients: Medical records of 76 consecutive patients treated for invasive epidermoid cancer of the anal canal between 1970 and 1999 were reviewed. Twenty-one patients were excluded because of inadequate staging information and/or follow-up of less than 12 months. Main Outcome Measures: Locoregional recurrence, survival, colostomy-free survival, and morbidity. Results: Fifty-five patients composed the study population. Ten were treated during decade 1 (1970-1979), 16 in decade 2 (1980-1989), and 29 in decade 3 (1990-1999). Mean age and sex distributions were similar. The prevailing primary treatment modality changed during the course of the study from sequential treatment (chemotherapy then radiation therapy then radical surgery) to concurrent chemoradiation (70{\%} and 0{\%} of cases, respectively, in decade 1 to 7{\%} and 76{\%} of cases, respectively, in decade 3). Locoregional control (50{\%}, 81{\%}, and 93{\%}; P=.01), crude survival (median, 28, 30, and 76 months), and colostomy-free survival (mean, 13, 90, and 80 months) improved during the 3 decades. There were no differences in major complications during the 3 decades (40{\%}, 56{\%}, and 41{\%}). Conclusion: Primary treatment with concurrent chemoradiation has improved the local recurrence, survival, and colostomy-free survival rates in patients with invasive epidermoid carcinoma of the anal canal without increasing major morbidity.",
author = "Whiteford, {M. H.} and Kenneth Stevens and S. Oh and Karen Deveney and R. Billingham and O'Connell, {T. X.} and Schecter, {W. P.} and Wren, {S. M.} and Schrock, {T. R.} and {De Virgilio}, C. and Russell, {T. R.} and Deveney",
year = "2001",
language = "English (US)",
volume = "136",
pages = "886--891",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - The evolving treatment of anal cancer

T2 - How are we doing?

AU - Whiteford, M. H.

AU - Stevens, Kenneth

AU - Oh, S.

AU - Deveney, Karen

AU - Billingham, R.

AU - O'Connell, T. X.

AU - Schecter, W. P.

AU - Wren, S. M.

AU - Schrock, T. R.

AU - De Virgilio, C.

AU - Russell, T. R.

AU - Deveney,

PY - 2001

Y1 - 2001

N2 - Hypothesis: The adaptation of new techniques in treatment of epidermoid carcinoma of the anal canal during the past 3 decades has improved clinical outcomes. Design: Retrospective consecutive case review. Setting: A university hospital and Veterans Affairs medical center. Patients: Medical records of 76 consecutive patients treated for invasive epidermoid cancer of the anal canal between 1970 and 1999 were reviewed. Twenty-one patients were excluded because of inadequate staging information and/or follow-up of less than 12 months. Main Outcome Measures: Locoregional recurrence, survival, colostomy-free survival, and morbidity. Results: Fifty-five patients composed the study population. Ten were treated during decade 1 (1970-1979), 16 in decade 2 (1980-1989), and 29 in decade 3 (1990-1999). Mean age and sex distributions were similar. The prevailing primary treatment modality changed during the course of the study from sequential treatment (chemotherapy then radiation therapy then radical surgery) to concurrent chemoradiation (70% and 0% of cases, respectively, in decade 1 to 7% and 76% of cases, respectively, in decade 3). Locoregional control (50%, 81%, and 93%; P=.01), crude survival (median, 28, 30, and 76 months), and colostomy-free survival (mean, 13, 90, and 80 months) improved during the 3 decades. There were no differences in major complications during the 3 decades (40%, 56%, and 41%). Conclusion: Primary treatment with concurrent chemoradiation has improved the local recurrence, survival, and colostomy-free survival rates in patients with invasive epidermoid carcinoma of the anal canal without increasing major morbidity.

AB - Hypothesis: The adaptation of new techniques in treatment of epidermoid carcinoma of the anal canal during the past 3 decades has improved clinical outcomes. Design: Retrospective consecutive case review. Setting: A university hospital and Veterans Affairs medical center. Patients: Medical records of 76 consecutive patients treated for invasive epidermoid cancer of the anal canal between 1970 and 1999 were reviewed. Twenty-one patients were excluded because of inadequate staging information and/or follow-up of less than 12 months. Main Outcome Measures: Locoregional recurrence, survival, colostomy-free survival, and morbidity. Results: Fifty-five patients composed the study population. Ten were treated during decade 1 (1970-1979), 16 in decade 2 (1980-1989), and 29 in decade 3 (1990-1999). Mean age and sex distributions were similar. The prevailing primary treatment modality changed during the course of the study from sequential treatment (chemotherapy then radiation therapy then radical surgery) to concurrent chemoradiation (70% and 0% of cases, respectively, in decade 1 to 7% and 76% of cases, respectively, in decade 3). Locoregional control (50%, 81%, and 93%; P=.01), crude survival (median, 28, 30, and 76 months), and colostomy-free survival (mean, 13, 90, and 80 months) improved during the 3 decades. There were no differences in major complications during the 3 decades (40%, 56%, and 41%). Conclusion: Primary treatment with concurrent chemoradiation has improved the local recurrence, survival, and colostomy-free survival rates in patients with invasive epidermoid carcinoma of the anal canal without increasing major morbidity.

UR - http://www.scopus.com/inward/record.url?scp=0034904103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034904103&partnerID=8YFLogxK

M3 - Article

C2 - 11485523

AN - SCOPUS:0034904103

VL - 136

SP - 886

EP - 891

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 8

ER -